Skip to main content

Table 2 Drug-related adverse events (n = 26 patients)

From: Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer

Category of AE

Grade 1

Grade 2

Grade 3

Grade 4

General disorders

(fatigue, pain, pyrexia, catheter-site edema, injection site burning)

6 (26.0%)

4 (17.4%)

-

-

GI disorders

(aphthous stomatitis, constipation, nausea)

4 (17.4%)

-

-

-

Nervous system disorders

(dysguesia)

2

(8.7%)

-

-

-

Skin and subcutaneous tissue disorders

(rash, alopecia)

5 (19.2%)

-

-

-

Laboratory investigations

(↑ ALT, ↑ AST, ↑ GGT, ↑ bilirubin)

-

1

(4.3%)

1

(4.3%)

1

(4.3%)

Metabolism and nutritional disorders

(anorexia, hyperglycemia)

2

(8.7%)

-

-

1

(4.3%)

Hepatobiliary disorder

(jaundice)

-

-

1

(4.3%)

-